The Vermont Pulmonary SCOR has developed a coordinated, comprehensive and systematic approach for studying mechanisms of pulmonary interstitial remodeling. This involves multidisciplinary applications of forefront research technologies from cell and molecular biology to sophisticated patient diagnosis, management and care. Program goals are to define organ, tissue and cell function as modified by specific agents involved in the etiology of occupational and immunologic lung disease to improve the scientific basis of diagnosis, management and treatment. Studies of specific human interstitial diseases will focus on the tissue and cellular pathology of developing and endpoint disease. Parallel studies of animal models of silica and asbestos mediated lung injury will focus on connecting the events of injury, inflammation and eventual tissue remodeling. Finally, specific cell culture and co-culture systems will be used to explore the cell biology of the remodeling process as it pertains to the vasculature and interstitium. Studies will define the roles of a limited number of pathogenic pathways concerned with chemotaxis, immune mediators such as IL-1 and macrophage growth factors, key lymphocyte and fibroblast cell subpopulations, modulation of fibroblast number and matrix output and the interactions of endothelial and smooth muscle cells. Specific findings and hypotheses developed from our studies of animal models and lund cells will continue to be applied to our targeted patient population as we continue to seek novel ways of approaching their diagnosis and management. This includes monitoring of the mineral content of lavage fluids and cells as markers of long-term exposure history. The studies are significant in terms of the multidisciplinary, collaborative and vertical approaches that will be used to define the importance of a selected number of etiologic pathways that lead to pulmonary pathology related to occupational and immunologic lung disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL014212-18
Application #
3106387
Study Section
(SRC)
Project Start
1976-12-01
Project End
1991-11-30
Budget Start
1988-12-01
Budget End
1989-11-30
Support Year
18
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Vermont & St Agric College
Department
Type
Schools of Medicine
DUNS #
066811191
City
Burlington
State
VT
Country
United States
Zip Code
05405
Quinlan, T R; Marsh, J P; Janssen, Y M et al. (1994) Dose-responsive increases in pulmonary fibrosis after inhalation of asbestos. Am J Respir Crit Care Med 150:200-6
Roggli, V L; Coin, P G; MacIntyre, N R et al. (1994) Asbestos content of bronchoalveolar lavage fluid. A comparison of light and scanning electron microscopic analysis. Acta Cytol 38:502-10
Quinlan, T; Spivack, S; Mossman, B T (1994) Regulation of antioxidant enzymes in lung after oxidant injury. Environ Health Perspect 102 Suppl 2:79-87
Mossman, B T; Janssen, Y M; Marsh, J P et al. (1991) Development and characterization of a rapid-onset rodent inhalation model of asbestosis for disease prevention. Toxicol Pathol 19:412-8
Mossman, B T; Marsh, J P; Sesko, A et al. (1990) Inhibition of lung injury, inflammation, and interstitial pulmonary fibrosis by polyethylene glycol-conjugated catalase in a rapid inhalation model of asbestosis. Am Rev Respir Dis 141:1266-71
Scott, S M; Buenaflor, G G; Orth, D N (1989) Immunoreactive human epidermal growth factor concentrations in amniotic fluid, umbilical artery and vein serum, and placenta in full-term and preterm infants. Biol Neonate 56:246-51
Ramage Jr, J E; Roggli, V L; Bell, D Y et al. (1988) Interstitial lung disease and domestic wood burning. Am Rev Respir Dis 137:1229-32
Fisher, G L; Mossman, B T; McFarland, A R et al. (1987) A possible mechanism of chrysotile asbestos toxicity. Drug Chem Toxicol 10:109-31
Mossman, B T; Gilbert, R; Doherty, J et al. (1986) Cellular and molecular mechanisms of asbestosis. Chest 89:160S-161S
Bell, D Y; Johnson, S M; Piantadosi, C A (1986) Elevated serum immunoglobulin G levels and bronchoalveolar lymphocytosis as predictors of clinical course in pulmonary sarcoidosis. Ann N Y Acad Sci 465:672-7

Showing the most recent 10 out of 11 publications